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Abstract: Low serum concentrations of micronutrients, intestinal abnormalities, and an 
inflammatory state have been associated with HIV progression. These may be ameliorated 
by micronutrients, N-acetyl cysteine, probiotics, and prebiotics. This review aims to 
integrate the evidence from clinical trials of these interventions on the progression of HIV. 
Vitamin B, C, E, and folic acid have been shown to delay the progression of HIV. 
Supplementation with selenium, N-acetyl cysteine, probiotics, and prebiotics has 
considerable potential, but the evidence needs to be further substantiated. Vitamin A, iron, 
and zinc have been associated with adverse effects and caution is warranted for their use.  
Keywords: HIV; AIDS; micronutrients; zinc; selenium; N-acetyl cysteine; probiotics; 
prebiotics 
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1. Introduction 
Infections caused by the Human Immunodeficiency Virus (HIV) are one of the leading public 
health concerns around the world. Over 33 million people are living with HIV and nearly three million 
became infected during 2008 [1]. While antiretroviral therapies (ART) are almost universally available 
in developed countries, only since the G8 summit in 2005 have they been made more readily 
accessible to patients in developing countries [2]. As there is considerable risk for developing ART-
induced toxic effects and metabolic dysfunction, the therapy is initiated only when the immune 
function is compromised (<350 CD4 cells/μL). For patients who have not developed severe immune 
deficiency, there is a significant void in methods to provide improved health. HIV causes certain 
dietary complications, including increased resting energy expenditure [3,4], enhanced oxidative  
stress [5], and a deleterious impact on the gastrointestinal system [6] that may require interventions 
specifically targeted to HIV. Therefore, the provision of a balanced and adequate diet is of prime 
importance for people living with HIV [7].  
Vitamins and minerals (referred to as micronutrients) have received widespread and recent attention 
as potential interventions to delay HIV progression [8]. Although micronutrient interventions for 
people living with HIV have been thoroughly reviewed [9], to our knowledge, no review articles have 
integrated the evidence of the potential of various bioactive components, such as N-acetyl cysteine, 
probiotics, and prebiotics with micronutrients for this population. These interventions could potentially 
delay the progression of HIV and therefore postpone the moment that a patient becomes immune-
compromised, and thus eligible for ART. Moreover, they could act in a complementary fashion with 
the ART, once the latter is initiated. Therefore, we present an assessment of randomized controlled 
trials (RCT) that evaluates the impact of micronutrients, N-acetyl cysteine, probiotics, and prebiotics 
on mortality, CD4 count, or HIV viral load among people living with HIV. Although this review 
emphasizes results from trials, it also briefly explores results from observational studies.  
2. Micronutrients 
The use of micronutrients among people living with HIV is widespread and comes from the concept 
that the virus causes a diverse range of nutrient abnormalities (reviewed in [10]). The depletion of 
micronutrients may occur through increased metabolic requirements, enhanced excretion, and 
intestinal mal-absorption (reviewed in [11]).  
Early studies of micronutrients tested the effect of single vitamins or minerals on delaying the 
progression of HIV. While some successes were reported, the focus has now turned to 
multivitamin/mineral supplementation as a more comprehensive approach to delaying HIV 
progression. The levels of micronutrients consumed by people living with HIV are often much higher 
than recommended by the Dietary Reference Intakes, potentially leading to adverse events [12]. 
Therefore, health care professionals should be aware of the beneficial and potential adverse effects of 
micronutrients in order to make informed, safe, and practical decisions for people living with HIV.  
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3. Vitamin A 
Vitamin A is essential for normal immune function, the maintenance of mucosal surfaces, and 
haematopoiesis [13]. Also, vitamin A supplementation is recognized for its ability to decrease 
morbidity and mortality rates for some infectious diseases [14]. Vitamin A deficiency has consistently 
been associated with an increase in mother-to-child transmission of HIV (MTCT) [15]. However, there 
is conflicting evidence coming from observational studies on HIV progression and vitamin A where in 
one study, a cohort (n = 179) of HIV infected drug users, reported increases in mortality and lower 
CD4 counts associated with lower serum vitamin A levels [16]. In contrast, another observational 
study of HIV-infected men (n = 311) did not find a relationship between lower serum retinol (vitamin 
A) status and HIV disease progression or CD4 count [17].  
There seems to be a potential role for vitamin A in children living with HIV. During an RCT in 
Tanzania, 687 children without signs of vitamin A deficiency who were admitted to the hospital with 
pneumonia were randomized. Some were given a large dose of vitamin A (400,000 IU) at baseline and 
again at four and eight months post-discharge. Among those, 58 were diagnosed with HIV and naïve to 
ART. Overall, a 49% reduction in mortality (p = 0.05) and a 92% reduction in diarrhea-related death 
(p = 0.01) was observed. These effects were more profound among the sub-group of children with HIV 
with a reduction in mortality of 53% (p = 0.04) and a reduction of 68% in AIDS related deaths  
(p = 0.05) [18]. Another RCT among 181 ART naïve HIV-infected children (15–36 months) in Uganda 
found similar results. Vitamin A supplementation (60 mg retinol) at three month intervals for a median 
of 17.8 months reduced mortality rates by 46% (p = 0.04), as well as persistent cough and chronic 
diarrhea. No effects were noted on CD4 count or HIV viral load [19]. Thus, there are potential benefits 
conferred by vitamin A supplementation for reducing the morbidity and mortality of children living 
with HIV in developing countries.  
Women living with HIV are at increased risk for experiencing adverse pregnancy outcomes, such as 
preterm birth and the delivery of low-birth-weight infants. Moreover, women can transmit the virus to 
their newborns through intrauterine, delivery, or breastfeeding routes. Research on the role of vitamin 
A in birth outcomes is critical as low levels of the vitamin have been associated with adverse 
pregnancy outcomes and vertical transmission of HIV [15]. To evaluate the effect of vitamin A 
supplementation on MTCT, RCTs were conducted among ART naïve pregnant women in South 
Africa, Malawi, and Tanzania. In South Africa, an RCT among 728 pregnant women showed that daily 
Vitamin A supplementation (5,000 IU and 30 mg β-carotene) and a large dose at delivery (200,000 IU) 
did not reduce MTCT or mortality among women and infants, although among those infants born pre-
term, vitamin A was associated with a reduction in MTCT [20]. In the Malawian RCT, pregnant 
women with HIV (n = 697) were randomized to receive daily vitamin A (3 mg retinol) or placebo. 
Infants whose mothers were in the vitamin A group had a higher birth weight (p = 0.05) and fewer 
incidences of anemia at six weeks, from 41% to 23% (p = < 0.001). This trial, however, did not show 
vitamin A supplementation to have an effect on MTCT [21]. 
Another trial among HIV-infected pregnant women in Tanzania (n = 1,078) did not show any 
effects of vitamin A supplementation (30 mg β-carotene plus 5000 IU vitamin A) on improved 
pregnancy outcomes. In contrast, vitamin A supplementation appeared to increase the MTCT of HIV 
by an additional 38% compared to the placebo (p = 0.009) [22]. Furthermore, vitamin A did not have 
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any effect on HIV-associated mortality or CD4 count during a median 71 months of follow-up among  
the women [23,24].  
In conclusion, two studies have indicated a potential benefit of vitamin A supplementation for 
children with HIV in developing countries who are naïve to ART. However, these benefits need to be 
confirmed in larger RCTs with HIV progression, mortality, and morbidity as primary outcomes. With 
respect to maternal supplementation, little evidence exists to support the use of vitamin A supplements 
in HIV-positive pregnant women. Rather, the possibility that maternal vitamin A supplementation 
could increase the risk of vertical transmission warrants caution for its use among this population. The 
notion that vitamin A supplementation reduced the benefits of multivitamin supplementation indicates 
that no profound benefits may exist for supplementing vitamin A among adults.  
Table 1. Randomized controlled trials on vitamin A and HIV progression.  
Reference Population, in- 
and exclusion 
criteria. 
Intervention 
and follow-up 
Primary 
outcomes 
Major findings Conclusions 
Fawzi 1998 
[22-24]  
Tanzania, 1078 
ART naïve 
pregnant women. 
Multifactorial 
design with Vit. 
A (5000 IU) and 
β-carotene (30 
mg) daily during 
pregnancy and 
lactation. 
Mortality, 
CD4 count 
and viral 
load. 
No differences in 
mortality, CD4 count or 
viral load among women 
or children. Vit. A 
increased MCTC. 
Vit. A does not 
reduce mortality 
among women 
but increased 
MTCT.  
Fawzi 1999 
[18] 
Tanzania, 58 ART 
naïve children 
admitted with 
pneumonia. 
Dose vit. A 
(400,000 IU) at 
baseline, 4 and 
8 months. 
Mortality Reduced overall and 
AIDS related mortality. 
Reduction on diarrhea 
related death. 
Vit. A reduces 
mortality among 
children admitted 
with acute 
infections. 
Coutsoudis 
1999 [20] 
South-Africa, 728 
ART naïve 
pregnant women. 
Vit. A (5000 
IU), β-carotene 
(30 mg) third 
trimester and 
vit. A (200,000 
IU) at delivery.  
MCTC, fetal 
and infant 
mortality. 
No reduction in MCTC, 
fetal or infant mortality. 
Reduction in preterm 
delivery. 
Vit. A 
administered to 
the mother does 
not affect fetal or 
infant mortality 
or MCTC. 
Kumwenda 
2002 [21] 
Malawi, 697 ART 
naïve pregnant 
women. 
Vit. A (3 mg) 
daily from 18-
28 weeks of 
gestation until 
delivery. 
MTCT, birth 
weight. 
Increase in birth weight 
and a reduction of the 
number of anemic 
children. No effect on 
MTCT. 
Vit. An 
administered to 
the mother 
increases birth 
weight and 
prevents anemia. 
No effect on 
MTCT 
Semba 
2005 [19] 
Uganda, 181 ART 
naïve children. 
Vit. A (60 mg) 
every three 
months for 18 
months. 
Mortality, 
CD4 count, 
HIV viral 
load. 
Reduction in mortality. 
No effect on CD4 count 
or viral load. 
Vit. A reduces 
mortality among 
children. 
MTCT = mother to child transmission 
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4. Vitamin B, C, E and Folic Acid 
B-vitamins are essential components of our immune system. Riboflavin deficiency hampers the 
generation of a humoral antibody response, vitamin B-6 deficiency reduces the maturation of 
lymphocytes, and vitamin B-12 deficiency impairs the function of neutrophils [25]. It is therefore not 
surprising that among people living with HIV, higher serum levels and intake of B vitamins have been 
associated with improved survival. In a large cohort study of people living with HIV in the US  
(n = 241), the highest quartile of intake for each B-group vitamin was independently associated with 
improved survival over the course of an eight-year follow-up: B1, (relative hazard (RH) = 0.60),  
B2 (RH = 0.59), B6, (RH = 0.45), and niacin (RH = 0.57) [26]. Higher serum levels of vitamin B12 
were also associated with delayed HIV progression [27]. These results were confirmed in a matched 
case-control study within a cohort of South African HIV patients. The median survival time of patients 
using vitamin B supplements (264 weeks) was significantly longer than of those not taking B vitamins  
(144 weeks) (p = 0.0014) [28].  
In several observational studies, vitamins C and E were found to be lower among people living with 
HIV [5,10]. These findings were confirmed by the group of Baum et al., who compared the nutrient 
levels of 108 HIV-infected gay men, almost all with high CD4 counts, to a similar group of HIV-
negative controls. In this seminal study, they found that deficiencies of vitamins B6, B12, A, E, and 
zinc were highly prevalent in the HIV-infected cohort. Thus, the conclusion was that HIV-infected 
individuals most likely require micronutrient intake in multiples of the DRI in order to maintain 
normal serum levels [29]. Lower levels of vitamin C and E were also related to significantly higher 
levels of oxidative stress [5], which presumably leads to increased viral replication [30]. In 
longitudinal studies, the dietary intake of vitamin E [31] and higher vitamin E serum levels [17] were 
associated with higher CD4 counts and a reduced risk of HIV progression [32].  
These findings were the impetus for studies assessing whether exogenous supplementation of 
vitamins could reduce oxidative stress and therefore potentially reduce HIV viral load. A pilot RCT  
(n = 49) among HIV patients receiving ART showed that the group receiving vitamin E (800 IU) and 
C (1,000 mg) for three months had significantly less oxidative stress (reduction of plasma peroxides 
and malondialdehyde) and a trend was seen (p = 0.1) towards a reduction of the viral load (−0.45 log10 
copies/ml) compared to the placebo group (+0.50 log 10 copies/mL) [33]. A study in Uganda with a 
short follow-up period of six weeks did not find a benefit of supplementation. The RCT (n = 141) 
among ART naïve HIV patients admitted with diarrhea showed that supplementation with a 
combination of vitamin A (10,500 IU), E (300 mg), Selenium (150 μg), and Zinc (200 mg) for two 
weeks did not reduce the length of time with diarrhea. Moreover, no effects were seen on mortality or 
CD4 count after the six weeks of follow-up. Low serum levels of vitamin A and E were confirmed to 
be predictors of mortality in this study, but exogenous supplementation did not increase these  
levels [32]. The expectation to see an effect of supplementation within such a short time-frame might 
have been unrealistic, as an impact on HIV progression is typically assessed over longer periods  
of time.  
The first long term study with HIV progression and mortality as primary outcome was conducted in 
Tanzania. A specific multivitamin combination of vitamins B, C, E, and folic acid (20 mg B1, 20 mg 
B2, 25 mg B6, 100 mg B3, 50 μg B12, 500mg C, 0.8mg folic acid) was repeatedly shown to increase 
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CD4 and CD8 counts, lower viral loads, and reduce mortality among ART naïve HIV infected women 
[34]. The large RCT (n = 1075) among pregnant women showed an increase in CD4 count from 
baseline (between 12 and 27 weeks gestation) to six weeks postpartum of 176 cells/μL vs. 112 cells/μL  
(p = < 0.001) in the placebo group. At 30 weeks postpartum, there was still a significant difference 
with an increase of 99 CD4 cells/μL in the multivitamin group vs. an increase of 59 CD4 cells/μL in 
the placebo group (p = 0.05), in addition to an increase in CD8 and CD3 cells. Furthermore, there were 
significant reductions in fetal death (Relative Risk (RR) = 0.61), low birth weight (RR = 0.56), and 
severe preterm birth (RR = 0.61) with multivitamin supplementation [34]. Long term (71 months) 
follow-up of this cohort showed that only 67 of 271 (25%) women receiving multivitamins died or 
developed stage 4 disease compared to 83 of 276 (30%) receiving placebo (RR = 0.71, P = 0.04). 
Moreover, women receiving multivitamin had on average a CD4 count of 48 cells/μL higher than the 
placebo group (p = 0.01), and a significantly lower viral load (p = 0.02) [24]. Multivitamins also 
reduced the risk of wasting (RR = 0.66, p = 0.02) and the incidence of weight loss episodes amongst 
HIV infected women [35]. Interestingly, women with impaired immunological (low lymphocyte count) 
and nutritional status (low haemoglobin levels) at baseline had reduced transmission of the virus from 
mother to child (RR = 0.37, p = 0.02) and decreased child mortality after 24 months (RR = 0.82, p = 0.08) 
when given multivitamins [22]. These results suggest that this particular multivitamin supplement (20 
mg B1, 20 mg B2, 25 mg B6, 100 mg B3, 50 μg B12, 500mg C, 0.8 mg folic acid) can be safely 
administered to pregnant women and has considerable immunological benefits.  
To assess the impact of the same multivitamin formula and selenium (200 μg daily for six weeks) 
on the infectivity (vaginal HIV shedding) of ART naïve women with HIV, an RCT (n = 400) was 
launched in Kenya. Although a relatively short intervention period of six weeks was used and the 
primary outcome was infectivity, the study confirmed the beneficial effects of the multivitamin 
supplement on the CD4 count (a mean of 23 cells/μL higher than placebo) and CD8 count (a mean of 
74 cells/μL higher than placebo). However, the trial showed a potential increase of HIV infectivity 
amongst women receiving supplements as the odds of detecting HIV infected vaginal epithelial cells 
increased 2.5 fold (p = 0.001), as well as the quantity of vaginal HIV RNA (p = 0.004) [36].  
In Bangkok, an RCT (n = 481) was conducted with an intervention using similar concentrations of 
vitamin B, C, E, and folic acid (24 mg B1, 15 mg B2, 40 mg B6, 30 μg B12, 400mg C, 3 mg A, 0.1 mg 
folic acid), but with the addition of vitamin A, zinc, and various other micronutrients (table 2.). 
Overall, a trend was seen towards a reduced mortality in the multivitamin group (RR = 0.53, p = 0.1) 
and a significant reduction among subgroups of those with a CD4 count <200 (RR = 0.37, p = 0.05) 
and <100 (RR = 0.26, p = 0.03). However, no effect was seen on viral load and CD4 count [37].  
A multivitamin combining vitamins A, B, C, D, E, zinc, copper, selenium, iodine, and folic acid 
with concentrations approximately 10 times lower than the Tanzanian combination was tested within a 
cluster randomized trial in Zambia. Households (n = 500 individuals) were randomized to receive the 
multivitamin combination for an average of 3.3 years [45]. No differences were seen in terms of CD4 
count or diarrhea incidence amongst those living with HIV who are ART naïve (n = 135). However, a 
significant difference in mortality was reported, as 20% (12/61) died during follow-up with placebo as 
compared to 5% (4/74) amongst the multivitamin supplemented group (p = 0.03 by log-rank test). 
In the United States, an RCT (n = 40) among HIV patients treated with ART who displayed related 
neurotoxicity, tested the impact of an intervention combining vitamins B, C, E, and folic acid in a daily 
Nutrients 2010, 2                            
 
 
632
dose approximately 6 times higher than the Tanzanian multivitamin combination and with the addition 
of vitamins A, D, zinc, N-acetyl cysteine (1.2 g), and various other minerals (Table 2). The 
intervention group experienced an increase in CD4 count from a baseline of 65 cells/μL after 12 weeks 
of supplementation, as compared to −6 cells/μL in the placebo group. However, no differences were 
seen in viral load or neuropathy scores [38]. 
In summary, several well designed RCTs have shown a considerable benefit of supplementation of 
vitamins B, C, E, and folic acid (20 mg B1, 20 mg B2, 25 mg B6, 100 mg B3, 50 μg B12, 500 mg C, 
0.8 mg folic acid) to ART naïve HIV patients. Although in subpopulations a decrease in MTCT has 
been reported, further studies are needed to assess if the potential increase in infectivity is present and 
may enhance HIV transmission. Furthermore, as one trial has shown potential for this approach among 
an ART-treated population, these results need to be confirmed by larger RCTs with long term follow-up.  
5. Vitamin D 
The interest in vitamin D and the immune system has been catalyzed by the discovery of vitamin D 
receptors in peripheral blood mononuclear cells involved in immune system regulation [39]. Vitamin 
D is involved in immune-related diseases, such as Ulcerative Colitis and Crohn’s Disease, and has 
recently gained attention for its mediating role in innate immunity and the body’s response to 
intracellular micro-organisms, such as Mycobacterium tuberculosis [40]. The role of vitamin D in HIV 
progression is less well understood. In Tanzania, an observational study (n = 1,078) was conducted 
within a trial to assess the effects of the vitamin D status of pregnant women on adverse pregnancy 
outcomes, MTCT, and child mortality [41]. Children born to mothers with low vitamin D levels had a 
64% greater risk of dying during follow-up and an overall 46% higher risk of contracting HIV. In this 
observational study of vitamin D status’ effects on child morbidity and mortality, a non-linear 
relationship was found between vitamin D levels and MTCT (p = 0.01), where the risk of MTCT 
decreased as the levels of vitamin D increased [41]. The only RCT with findings on vitamin D and 
HIV progression to date was conducted in Guinea-Bissau. The trial (n = 367) among Tuberculosis 
(TB) patients assessed the impact of supplements of vitamin D every four months (100,000 IU of oral 
cholecalciferol) over a 12-month period [42] on mortality and the clinical severity of TB (Table 2). 
Vitamin D did not appear to improve the severity of tuberculosis, nor was there an impact on mortality 
in both the complete group and the sub-group infected with HIV (n = 135) [42]. Therefore, there is 
insufficient evidence to recommend vitamin D use among people living with HIV. Larger RCTs are 
warranted, as there might be considerable potential. 
Table 2. Randomized controlled trials on vitamin B, C, D, E and folic acid, and HIV 
progression.  
Reference Population, in- 
and exclusion 
criteria. 
Intervention 
and follow-up 
Primary 
outcomes 
Major findings Conclusions 
Allard 1998 
[35] 
Canada, 49 
individuals 
receiving ART.  
Daily vit. E 
(800 IU) and C 
(1000mg) for 3 
months. 
HIV viral 
load, 
oxidative 
stress 
Trend towards 
reduction in viral load. 
Significant reduction of 
oxidative stress.  
Vit. E and C may 
reduce viral load 
and reduces 
oxidative stress. 
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Table 2. Cont. 
Kelly 1999 
[34] 
Zambia, 141 ART 
naïve patients 
admitted with 
diarrhea. 
Daily vit. A 
(10.500 IU), C 
(300 mg), E 
(300 mg) 
Selenium 
(300 μg) and 
Zinc (200 mg) 
for two weeks.  
Diarrhea, 
mortality, 
serum A and 
E, CD4 
count. 
No difference in length 
of diarrheal episodes, 
mortality or CD4 count 
after 6 weeks. 
No additional value 
of multivitamin to 
treatment of 
diarrhea among 
HIV patients. 
Fawzi 
1998.[22,2
4,,43]  
Tanzania, 1078 
ART naïve 
pregnant women. 
Multifactorial 
design with Vit. 
B, C, E and 
folic acid1. 
MTCT, 
Mortality, 
CD4 count 
and viral 
load. 
No effect on MTCT, 
Reduced mortality, 
delayed HIV 
progression, increased 
CD4, CD8 count and 
decreased viral load for 
the multivitamin.  
Multivitamin does 
not reduce MTCT 
but reduces HIV 
progression and 
mortality among 
children and 
pregnant women.  
Jiamton 
2003 [44] 
Bangkok, 481 ART 
naïve individuals 
with CD4 count 50 
- 500 cells/μL.  
Daily vit. A, B, 
C, D, E, K, zinc, 
selenium and 
various 
minerals2 for 48 
weeks. 
Mortality, 
CD4 count 
Reduction of mortality 
with no differences in 
viral load and CD4 
count. 
Micronutrients 
reduce mortality 
among people 
living with HIV. 
McClelland 
2004 [36] 
Kenya, 400 ART 
naïve women. 
Daily vit. B, C, 
E, folic acid1 
and selenium 
(200 mg) for 6 
weeks. 
HIV 
infectivity 
Increase in HIV 
infectivity. Increase in 
CD4 and CD8 count 
and no difference in 
viral load. 
Multivitamin may 
increase HIV 
infectivity. 
Kaiser 
2006 [38]  
United states, 40 
individuals 
receiving ART and 
signs of ART 
related neuropathy. 
Twice daily vit. 
A, B, C, D, E, 
zinc, selenium, 
NAC and 
various 
minerals3 for 12 
weeks. 
CD4 count, 
viral load, 
neuropathy, 
safety 
parameters. 
Intervention increased 
CD4 count with no 
effect on viral load or 
neuropathy. 
Micronutrients and 
NAC increases 
CD4 count and was 
found to be safe. 
Kelly 2008 
[45] 
Uganda, cluster 
randomized trial 
among 500 
individuals of 
which 135 HIV 
infected and ART 
naïve. 
Daily vit.A, B, 
C, D, E, folic 
acid, selenium, 
iron, zinc, 
copper, iodine4.  
Diarrhea 
incidence, 
CD4 count, 
mortality. 
Intervention did not 
reduce the incidence of 
diarrhea. No effect on 
CD4 count but decrease 
in mortality. 
Low dose 
multivitamin may 
reduce mortality. 
Wejse 2009 
[42] 
Guineau-Bassau, 
West Africa, 367 
TB-infected, 131 
co-infected with 
HIV and ART 
naïve. 
Vitamin D 
100,000 IU 
every 3 months 
for 12 months 
Clinical 
severity 
score of TB 
and overall 
mortality at 
12 months 
No difference in 
clinical severity or 
mortality between 
vitamin D and control 
group.  
Vit. D not effective 
at improving 
clinical outcomes 
of TB.  
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MTCT = Mother to child transmission, TB = Tuberculosis 
1. Micronutrient supplement included vitamin B1 20 mg , vitamin B2 20 mg, vitamin B6 25 mg, vitamin B3 100 mg, 
vitamin B12 50 μg, vitamin C 500 mg and folic acid 0.8 mg. 
2. Micronutrient supplement included vitamin A 3,000 μg, beta-carotene 6 mg, vitamin D3 20 μ g, vitamin E 80 mg, 
vitamin K 180 μg, vitamin C 400 mg, vitamin B1 24 mg, vitamin B2 15 mg, vitamin B6 40 mg, vitamin B12 30 μg, folacin 
100 μ g, panthothenic acid 40 mg, iron 10 mg, magnesium 200 mg, manganese 8 mg, zinc 30 mg, iodine 300 μg, copper 3 
mg, selenium 400 μg, chromium 150 μg and cystine 66 mg. 
3. Micronutrient supplement included N-acetyl cysteine 1,200 mg , acetyl L-carnitine 1,000 mg, α-lipoic acid 400 mg, β-
carotene 20,000 IU, vitamin A 8,000 IU, vitamin C 1,800 mg, thiamine 60 mg , riboflavin 60 mg, pantothenic acid 60 mg, 
niacinamide 60 mg, inositol 60 mg, vitamin B6 260 mg, vitamin B12 2.5 mg, vitamin D 400 IU, vitamin E 800 IU,  
folic acid 800 μg, Ca 800 mg, Mg 400 mg, Se 200 μg, Iodine 150 μg, Zn 30 mg, Cu 2 mg, B 2 mg, K 99 mg, Fe 18 mg,  
Mn 10 mg, biotin 50 μg, Cr 100 μg, Mo 300 μg, choline 60 mg, bioflavonoid complex 300 mg, L-glutamine 100 mg, and 
betaine HCL 150 mg. 
4. Micronutrient supplement included Vitamin A as β-carotene 4,8 mg, vitamin B1 1,4 mg , vitamin B2 1,4 mg, vitamin B6 
1,6 mg, vitamin B12 2,6 μg, vitamin C 18 mg, vitamin D35 mg, vitamin E 10 mg, iron 30 mg, zinc 15 mg, copper 12 mg, 
selenium 65 μg iodine 150 μg and folic acid 400 μg. 
6. Iron 
Iron deficiency is the most common nutritional deficiency in the world, and is a condition mainly 
affecting women. Among people living with HIV, anemia (defined as low haemoglobin) is highly 
prevalent and is associated with increased mortality [46,47] and enhanced HIV progression [47]. 
Although anemia can generally be treated by iron supplementation, various clinical observations have 
raised the concern that iron supplementation may adversely affect HIV progression and increase 
mortality [48]. Firstly, in a retrospective study among thalassemia major patients (n = 64), the rate of 
progression of HIV was significantly faster amongst those receiving lower doses of the iron chelating 
agent, desferrioxamine, and who have higher serum ferritin concentrations [49,50]. Second, the 
concurrent administration of low doses of iron with dapsone for the prophylaxis of Pneumocystis 
carinii pneumonia in HIV-positive patients was associated with an increased risk of mortality in a 
randomized study among 196 HIV patients [51]. In contrast, the administration of Dapsone for the 
prophylaxis of Pneumocystis carinii without a low dose of iron did not lead to excess mortality in 
another trial [52]. Thirdly, a study on polymorphisms of haemoglobin-binding haptoglobin indicated 
that the haptoglobin 2-2 polymorphism is associated with higher iron stores and shortened survival 
among HIV patients [53]. Finally, a retrospective study of iron load in bone marrow macrophages 
among HIV patients suggested that high iron stores were associated with a shorter survival in HIV-
positive patients [54]. As none of these observations could provide conclusive evidence for an adverse 
effect of iron on HIV progression, two prospective studies were conducted. Within a larger RCT of 
non-anemic participants (n = 181), a subpopulation of ART naïve HIV patients (n = 45) was studied to 
assess the effect of daily 60 mg iron supplementation (twice weekly for 4 months) on HIV viral load 
(Table 3). In this small study, no increase in HIV viral load could be detected [55]. In the United 
States, an RCT was conducted among female drug users infected with Hepatitis C Virus (n = 485) and 
among them, a subgroup co-infected with HIV (n = 138), of whom 50 were treated with ART. An 
assessment was made on whether iron supplementation (18 mg daily) would increase HIV viral load 
and reduce anemia over a 12-month period. At follow-ups, the proportion with anemia in the iron 
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group was only 21% vs. 31% in the placebo group (P = 0.03) at 6 months and, respectively, 26% 
versus 30% (P = 0.5) at 12 months. Furthermore, no increase in HIV viral load could be detected [56]. 
This study could exclude a large increase in HIV viral load due to iron supplementation, but was not 
powered to detect small increases over a larger period of time. Furthermore, the conclusions from this 
study cannot readily be extrapolated to other HIV populations. It remains to be determined what the 
influence is of iron supplementation among patients who are receiving ART. Given the potential 
adverse role of iron in HIV progression, caution is warranted for iron supplementation among HIV 
infected populations. Routine supplementation without a specific indication is contra-indicated. 
Table 3. Randomized controlled trials on iron supplementation and HIV progression. 
Reference Population, in- 
and exclusion 
criteria 
Intervention 
and follow-up 
Primary 
outcomes 
Major findings Conclusions 
Olsen 2004 
[55] 
Kenya, 45 ART 
naïve HIV patients. 
60 mg iron 
twice weekly 
for 4 months. 
HIV viral load. No increase in HIV viral 
load. 
Low dose iron 
can be safely 
administered.  
Semba 
2007 [56] 
United States, 485 
HCV infected of 
which 138 co-
infected with HIV 
of whom 50 
receiving ART. 
18 mg iron daily 
for 12 months.  
HCV and HIV 
viral load, 
anemia. 
No increase in HCV or 
HIV viral load. Reduced 
occurrence of anemia. 
Iron is safe 
administered 
and is 
effective in 
treating 
anemia. 
HCV = Hepatitis C Virus. 
7. Zinc 
Various studies have investigated the role of zinc in HIV disease progression. The immunologic 
consequences of zinc deficiency are manifold, given the involvement of the mineral in basic cellular 
processes, which are essential in immunological mechanisms [57]. Consequently, zinc deficiency has 
been associated with a higher susceptibility to infectious diseases, such as pneumonia, malaria, and 
diarrhea [58]. There is evidence that zinc deficiency amongst people living with HIV may account for 
an improper maturation of CD4 count cells mediated through low levels of the zinc-dependent 
hormone, thymuline. This may lead to a less effective immune response and a higher susceptibility to 
opportunistic infections [59]. However, evidence for the relationship between zinc status and HIV is 
inconclusive. In an observational study of asymptomatic HIV-infected men in the United States, high 
zinc intake has been shown to be significantly associated with faster HIV progression and an increased 
mortality amongst men [17,60]. In contrast, another observational US cohort study of HIV positive 
men suggested that higher serum zinc levels were inversely associated with mortality [61].  
A first interventional study was conducted in Italy among 57 Zidovudine treated HIV patients that 
had developed or were at risk of developing AIDS (Table 4.). Those supplemented daily with zinc  
(45 mg) for 30 days experienced, at follow-up, a lower frequency of opportunistic infections after 24 
months and an increase in CD4 count after four months (compared to the controls) [59]. To assess the 
safety of daily zinc supplementation (10 mg) to ART naïve children with HIV, an RCT (n = 96) was 
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conducted in South Africa. This trial did not show any apparent benefit of zinc supplementation. No 
differences were found in CD4 count, viral load, or haemoglobin concentration, while supplementation 
was found to be safe [62]. This trial was followed by the largest study to date on zinc supplementation 
for people living with HIV and was aimed at assessing the potential benefits of zinc supplementation 
on pregnancy outcomes. The study population of the RCT (n = 400) consisted of pregnant ART naïve 
women with HIV in Tanzania [63]. All women received the multivitamin supplement (discussed in the 
section on vitamins B, C, E, and folic acid) and were randomized to receive, in addition, either a 
placebo or a 25 mg daily dosage of zinc between recruitment and six weeks after delivery. The results 
showed no differences in pregnancy outcomes, HIV transmission, CD4 or CD8 count, and viral load. 
However, zinc supplementation was inversely associated with haemoglobin levels, and was related to a 
threefold increase in the probability of wasting (RR = 2.7, p = 0.03) [64].  
In conclusion, although an initial trial has shown potential benefits of zinc supplementation among 
ART treated patients, these results have not been replicated in a trial among ART naïve pregnant 
women. Further research is warranted to assess whether there is a potential role for zinc among HIV 
patients treated with ART.  
Table 4. Randomized controlled trials on zinc and HIV progression. 
Reference Population, in- 
and exclusion 
criteria 
Intervention 
and follow-up 
Primary 
outcomes 
Major findings Conclusions 
Mocchegiani 
1995 [59] 
Italy, 57 AZT 
treated patients. 
At risk or 
developed 
AIDS. 
Zinc (45 mg) for 
30 days. 
Incidence 
opportunistic 
infections, 
body weight. 
Reduction opportunistic 
infections, stabilization or 
increase body weight, 
CD4 count, thymulin. 
Zinc increases 
CD4 count. 
Bobat 2005 
[62] 
South Africa, 96 
ART naïve 
children. 
Daily zinc 
(10 mg) for 6 
months.  
CD4 count, 
viral load and 
diarrhea 
incidence. 
No difference in CD4 
count or viral load but a 
reduction in watery 
diarrhea. 
Zinc safe 
among 
children with 
HIV. 
Fawzi 2005 
[63,64] 
Tanzania, 400 
ART naïve 
pregnant 
women. 
Daily zinc (25 
mg) additional 
to multivitamin 
1 until 6 weeks 
after delivery. 
CD4 count, 
viral load and 
MTCT. 
No effects on CD4 count, 
viral load and MCTC but 
adverse effects on 
haemoglobin level and an 
increase risk of wasting. 
Zinc has no 
impact on HIV 
progression 
and may cause 
adverse 
effects. 
MTCT = Mother to child transmission; 1. Micronutrient supplement included vitamin B1 20 mg , vitamin B2 20 mg, 
vitamin B6 25 mg, vitamin B3 100 mg, vitamin B12 50 μg, vitamin C 500 mg and folic acid 0.8 mg. 
8. Selenium 
The trace element selenium has been suggested to be a key nutrient for people living with HIV. 
Lower serum concentrations of selenium in both adults and children infected with HIV have been 
linked to increased mortality [65] and an increased viral load [66-68]. The role of selenium in 
immunity and antioxidant defence may be the underlying mechanism of an enhanced HIV progression 
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with lower levels of the micronutrient [69]. These observational findings instigated clinical trials to 
assess whether selenium supplementation could have an impact on HIV viral load, CD4 counts, or 
HIV progression (Table 5). An earlier pilot RCT among ART treated HIV patients (n = 52) showed 
that selenium supplementation (100 μg) could enhance the antioxidant status of HIV patients [70]. A 
larger RCT (n = 186, of which 124 were receiving ART) showed that daily supplementation with 
selenium (200 μg) did not affect CD4 count levels or viral load after two years of follow-up. However, 
a smaller proportion (25%) among the selenium group experienced a substantial decline in CD4 count 
(>50 cells/μL) when compared to the placebo group (46%, p = 0.01). In addition, the relative risk of 
being admitted at a hospital was 2.4-times lower among the selenium supplemented group in 
comparison to the placebo group (p = 0.008) [71]. In a more recent RCT among 262 HIV-infected 
patients (192 receiving ART), nine-month supplementation with selenium (200 μg daily) resulted in an 
increase in CD4 count (p = 0.04) and a decrease in viral load (p = 0.02) [72].  
To assess the impact of selenium supplementation on mother and child mortality, a large RCT  
(n = 913) was conducted amongst pregnant women in Tanzania. Daily selenium (200 μg) 
supplementation until six months post partum did not affect CD4 count, viral load, or overall mother 
and child mortality. However, at six weeks after delivery, a reduction of 57% in child mortality was 
found (p = 0.05) amongst the selenium supplemented group [73]. The authors concluded that the lack 
of a beneficial effect of selenium supplementation on HIV progression may have been due to the low 
prevalence of ART use and selenium deficiency amongst their study population or because of a 
reduced effect of selenium amongst patients already supplemented with micronutrients [73].  
Table 5. Randomized, placebo controlled trials on selenium and HIV progression. 
Reference Population, in- 
and exclusion 
criteria 
Intervention 
and follow-up 
Primary 
outcomes 
Major findings Conclusions 
Constans 
1996 [70] 
France, 52 
individuals 
receiving ART. 
Selenium 
(100 μg) vs. β-
carotene (30 
mg) vs. placebo 
CD4 count 
and serum 
anti-oxidant 
level. 
Both selenium and β-
carotene did not have an 
impact on the CD4 count 
but enhanced serum 
antioxidant levels. 
Selenium and 
β-carotene 
improve anti-
oxidant status. 
Burbano 
2002 [71] 
United states, 186 
injection drug 
users of whom 124 
receiving ART. 
Daily Selenium 
(200 μg) for 2 
years. 
CD4 count 
and hospital 
admissions 
No differences in CD4 
count and viral load. 
Reduction in number with 
drop in CD4 count of >50 
cells/μL and risk of 
admission was lower. 
Selenium may 
reduce decline 
in CD4 count 
and risk of 
hospital 
admission.  
Hurwitz 
2007 [72] 
United states, 262 
individuals of 
whom 192 
receiving ART 
Daily selenium 
(200 μg) for 9 
months. 
CD4 count, 
viral load. 
Increase in CD4 count, and 
decrease in viral load. 
Selenium 
reduces HIV 
progression. 
Kupka 
2008 [73] 
Tanzania, 913 
ART naïve 
pregnant women. 
Daily selenium 
(200 μg) until 6 
months after 
delivery. 
Mortality, 
CD4 count, 
viral load. 
No differences in mortality, 
CD4 count or viral load. 
Selenium does 
not affect HIV 
progression. 
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At present, there is no support for providing selenium supplements to HIV patients who are not 
selenium deficient and who are already receiving a high-dose multivitamin. Although two RCTs have 
shown that selenium supplementation can potentially reduce the viral load and enhance the 
immunological status of patients treated with ARTs, well designed trials with a long term follow-up 
and an appropriate sample size among similar populations are needed to substantiate the evidence for 
the use of selenium. 
9. N-acetyl Cysteine  
Glutathione (GSH) is a principal regulator of oxidative stress, which occurs in the intracellular 
space and on cellular membranes. HIV-infected people tend to have abnormal GSH levels in various 
components of the immune-system, including CD4 cells. In vitro studies have shown that lower 
intracellular GSH levels decrease cell survival and increase NF-ĸB activation and consequently, HIV 
replication. Observational studies have linked GSH deficiency directly to patient survival [74]. 
Various interventions have been tested to increase GSH levels to normal among HIV patients. N-acetyl 
cysteine (NAC), a pro-drug used to replenish GSH after paracetamol intoxication, was shown to 
restore normal GSH levels among HIV patients [74-76].  
One of the first RCTs was conducted by Herzenberg et al., who randomized HIV patients  
(n = 246, mixed ART status) with low GSH levels to NAC supplementation (3.2–8 g daily) or to a 
placebo for eight weeks, followed by an open label treatment of two years (Table 6). The results 
suggested that those using NAC were more likely to survive during follow-up (RR = 1.8, p = 0.02), but 
no CD4 count or viral load data were collected [74]. A smaller RCT (n = 45) among ART naïve HIV 
patients taking NAC supplementation (400 mg) for four months showed significantly reduced TNF-α 
levels, but no effect upon CD4 count during the study. However, it was noted that the NAC 
supplemented group had a less profound decline in CD4 count when compared to the 36 months before 
randomization (p = <0.05) [75]. Another RCT (n = 29) assessing the effect of daily NAC 
supplementation (0.6–3.6 g) during 7 months did not show differences in CD4 and CD8 counts, 
although an increase in natural killer (NK) cell activity (p = <0.05) was noted [76]. A controlled cross-
over study (n = 24) showed a trend towards an increased CD4 count and CD4/CD8 ratio during daily 
supplementation of NAC (600 mg) when combined with selenium (500 μg) [77]. Serum GSH 
concentrations were not affected by supplementation.  
Another approach to replenishing GSH levels is through the supplementation of whey protein, 
which is a source of the amino acid, cysteine. This intervention was shown to be effective in enhancing 
GSH levels in a small RCT amongst patients receiving ART (n = 30) [78]. The effectiveness of whey 
protein on CD4 count levels was assessed in a larger RCT, which was also amongst ART treated 
patients (n = 59). In this study, the whey supplemented group (40 g daily) had an increase of CD4 
count of 31 cells/μL, compared to 15 cells/μL amongst the placebo group during the 12-week follow-
up (p = 0.03) [79].  
Replenishing GSH stores with either NAC or whey protein appears to have a beneficial impact 
upon the immune function of people living with HIV. These results are promising and warrant the 
conduct of a large RCT to assess either of the effects of these supplements upon the progression  
of HIV.  
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Table 6. Randomized, placebo controlled trial on cysteine and HIV progression. 
Reference Population, in- 
and exclusion 
criteria 
Intervention 
and follow-up 
Primary 
outcomes 
Major findings Conclusions 
Akerlund 
1991 [75] 
Sweden, 45 ART 
naïve individuals 
with CD4 > 200 
cells/uL 
Daily NAC (400 
mg) for 4 
months. 
CD4 count 
and clinical 
signs and 
symptoms 
No effect on CD4 count. 
But increased level of GSH, 
reduced TNFα levels and 
reduced decline of CD4 
count than before baseline. 
NAC may 
reduce decline 
in CD4 count 
and restores 
GSH levels. 
Herzenberg 
1997 [74] 
United states, 246 
individuals with 
low glutathione 
levels (ART status 
unknown). 
Daily NAC 
(3.2–8.0 g) for 8 
weeks, followed 
by open label 
treatment for 2 
years. 
Mortality, 
GSH levels. 
Supplementation restored 
GSH levels and reduced 
mortality. 
NAC restores 
GSH levels 
and may 
reduce 
mortality. 
Look 1998 
[77] 
Germany, Cross-
over RCT, 24 ART 
naïve individuals. 
Daily NAC (0.6 
g) and selenium 
(500 μg) for 24 
weeks. 
CD4 count, 
GSH levels 
Trend towards increase in 
CD4 count and CD4/CD8 
ratio at particular time 
points, no increase in GSH 
level. 
NAC and 
selenium may 
improve 
immune status. 
Breitkreutz 
2000 [76] 
Germany, 29 ART 
naïve individuals. 
Daily NAC 
(0.6–3.6 g) for 7 
months. 
CD4 count, 
GSH levels 
Supplementation restored 
GSH levels, no difference in 
CD4 or CD8 cells but 
increase in NK cell activity. 
NAC restores 
GSH levels 
and may 
enhance 
antiviral 
response. 
Micke 2002 
[78] 
Germany, 30 
individuals 
receiving ART. 
Daily whey 
protein (45 g) 
for 6 months. 
GSH levels, 
CD4 count 
and body 
weight. 
Increase in GSH levels, no 
differences in CD4 count or 
body weight. 
Whey protein 
increases GSH 
levels. 
Sattler 
2008 [79] 
United states, 59 
individuals 
receiving ART. 
Daily whey 
protein (40 g) 
for 12 weeks. 
Weight, lean 
body mass  
No difference in weight or 
lean body mass, but 
significant increase in CD4 
count. 
Whey protein 
increases CD4 
count.  
NAC = N-acetyl cysteine, GSH = gluthathione 
10. Probiotics  
Recent findings suggest that the mucosal immune system is rapidly and preferentially [80] depleted 
of CD4 cells during initial HIV infection. This is associated with an enhanced intestinal epithelial 
permeability, as evidenced by increased levels of lipopolysaccharides (LPS) [81]. Plasma LPS levels 
correlate with systemic inflammation, which may drive HIV replication and consequently, progression 
of the disease [82]. Also, HIV is associated with increased markers of intestinal inflammation [83] and 
has been shown to elicit a Th-2 skewed immune response, which may inhibit an effective antiviral 
response [84,85]. The gut microbiota of people living with HIV is dramatically different than that of 
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healthy populations. The former group have a notable reduction of both lactobacilli and bifidobacteria, 
while pathogenic species, such as Candida albicans and Pseudomonas aeruginosa, are more 
prominent [83,86].  
Probiotics are defined as “live micro-organisms, which, when administered in adequate amounts, 
confer a health benefit on the host” [87]. Studies indicate that specific probiotic strains may reduce 
epithelial permeability [88-91], down-regulate systemic and mucosal inflammation [92,93,94], and 
regulate “allergy-like” Th-2 responses [95]. Therefore, specific probiotic strains may potentially 
ameliorate HIV-induced changes to the mucosal and systemic immune systems.  
To test this hypothesis, a small RCT (n = 77, of which 42 were receiving ART) was conducted in 
Brazil amongst children living with HIV. After daily supplementation of candidate probiotic 
containing strains of Bifidobacterium bifidum and Streptococcus thermophilus (2.5 × 1010 colony 
forming units) for two months, the CD4 count among the treatment group increased +118 cells/μL 
versus a decrease of −42 cells cells/μL among the placebo group (p = 0.05). However, the viral load 
was not measured, and no reduction in diarrhea incidence was shown [96]. Encouraging results were 
also reported in a small RCT (n = 24) among HIV infected women in Nigeria (table 7). After four 
weeks of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 supplementation, the 
probiotic group experienced an increase of +6.7 CD4 cells/μL, compared to a decrease of −2.2 CD4 
cells/μL among the placebo group (p = 0.05) [97]. Although preliminary results are encouraging for 
probiotic supplementation for people living with HIV, the trials conducted to date have not had 
sufficiently large sample sizes or length of follow-up to substantiate the evidence for increases in CD4 
count or clinical parameters of HIV progression.  
11. Prebiotics  
A prebiotic is defined as “a selectively fermented ingredient that allows specific changes, both in 
the composition or activity, in the gastrointestinal microflora that confers benefits upon host well-
being and health” [98]. Specific prebiotic formulations have been shown to reduce intestinal 
permeability [99], down-regulate mucosal inflammation [100], and enhance a systemic Th1 immune 
profile [101,102]. A recently conducted RCT (n = 57) was the first to show the potential of prebiotic 
supplementation amongst a population living with HIV. Participants were randomized to receive a 
placebo, a single dose (15g), or a double dose (30g), of a specific mixture of galacto-oligosacharides 
(GOS), which are long-chain fructans and pectin-derived oligosaccharides. The prebiotic intervention 
resulted in increased bifidobacterial levels and reduced numbers of the pathogenic Clostridium 
histolyticum cluster [103]. Furthermore, the prebiotic intervention was associated with reduced 
CD4+/CD25+ cell activation and an improved Natural Killer (NK) cell activity. Effects on CD4 count 
or viral load were not reported [104]. Prebiotics can be supplemented with probiotics (once combined, 
they are referred to as synbiotics). A large RCT in Malawi (n = 795) testing the effect of 
SynbioticForte 2000 (Table 5) on malnutrition also included a proportion of HIV infected children  
(n = 361). Although there was no improvement in nutritional cure, there was an overall reduction in 
outpatient mortality, including a trend towards a reduced mortality among the subgroup of HIV 
infected children [105]. In conclusion, the application of prebiotics to reverse HIV induced intestinal 
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changes has considerable potential, and further design and testing of products specifically for HIV  
is warranted. 
Table 7. Randomized, placebo controlled trials on probiotics and prebiotics and HIV 
progression. 
Reference Population, in- 
and exclusion 
criteria 
Intervention 
and follow-up 
Primary 
outcomes 
Major findings Conclusions 
Trois 2007 
[96] 
Brazil, 77 children 
(42 receiving 
ART). 
Daily B. bifidum 
and S. 
thermophilus 
(2.5 x 1010 
CFU/ml) for 
two months. 
CD4 count 
and diarrhea 
prevalence. 
Increase in CD4 count, no 
reduction in diarrhea 
prevalence. 
The candidate 
probiotic 
strains may 
increase CD4 
count among 
children. 
Land 2008 
[104] 
Italy, 57 ART 
naïve individuals. 
Daily prebiotic 
15 g or 30 g for 
12 weeks1. 
NK cell 
activity and 
CD4 cell 
activation. 
Increased NK cell activity, 
reduced CD4+/CD25+ cell 
activation and beneficial 
effect of intestinal flora. 
Prebiotics may 
reduce HIV 
associated 
hyper-immune 
activation and 
enhance anti-
viral response.  
Anukam 
2008 [97] 
Nigeria, 24 ART 
naïve women 
Daily L. 
rhamnosus GR-
1 and L. reuteri 
RC-14 (>1.0 x 
107 CFU/mL) 
for 4 weeks. 
CD4 count 
and 
resolution of 
diarrhea 
Increase in CD4 count and 
faster resolution of diarrhea. 
The probiotics 
may increase 
the CD4 count 
and reduce the 
length of 
diarrheal 
episodes. 
Kerac 2009 
[105] 
Malawi, 361 ART 
naïve children with 
malnutrition. 
Daily Synbiotic 
Forte 20001 for 
9 months. 
Nutritional 
cure, 
mortality. 
No difference in nutritional 
cure but trend towards 
reduced mortality. 
Synbiotic may 
reduce 
mortality. 
Lange 2009 
[106] 
Various countries, 
340 ART naïve 
individuals. 
Daily prebiotics, 
NAC, bovine 
colostrum, 
omega-3 
PUFA’s and 
micronutrients 
for one year2. 
CD4 count 
and viral 
load. 
Increase in CD4 count, no 
decrease in viral load. 
Intervention 
increases CD4 
count and may 
delay the 
progression of 
HIV. 
CFU = colony forming unit, NAC = N-acetyl cysteine, NK = natural killer 
1. Synbiotic included, Pediococcus pentosaceus, Leuconostoc mesenteroides, Lactobacillus paracasei ssp paracasei, and 
Lactobacillus plantarum (10¹¹ colony-forming units of bacteria total) and four prebiotic fermentable bioactive fibers (2.5 g 
of each per 10¹¹ bacteria) (oat bran [rich in β-glucans], inulin, pectin, and resistant starch). 
2. Formula included short-chain Galactooligosaccharides (scGOS), long-chain Fructooligosaccharides (lcFOS) and Acidic 
Oligosaccharides from pectin hydrolysate (AOS) (ratio 9,1,10), NAC, bovine colostrum, omega-3 PUFA’s  
and micronutrients. 
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12. Conclusions  
The beneficial effects of supplementation with vitamins B, C, E, and folic acid to HIV patients have 
been firmly established, and enough evidence exists to recommend the Tanzanian supplement to 
pregnant women with HIV in developing countries. The potential beneficial effects of this 
multivitamin supplement among HIV patients who are being treated with ARTs and among male HIV 
patients remain to be determined.  
Among children living with HIV, evidence indicates that vitamin A is beneficial in reducing 
morbidity and mortality in developing countries. Further large RCTs with HIV progression and 
mortality as primary outcomes are warranted to substantiate these findings. Among pregnant women 
with HIV, there is little evidence to recommend vitamin A supplementation. The potential increase in 
MTCT found in one study due to vitamin A supplementation warrants caution for its use among  
this population.  
Only one RCT has been conducted to date to assess the effect of vitamin D on HIV progression. 
The vitamin did not show apparent benefits. This might have been due to an insufficient dose or a 
relatively small sample size of the sub-population co-infected with HIV. Therefore, a large RCT with 
HIV progression as the primary outcome and a potentially different dose would be of great value. 
A small RCT on zinc has provided some evidence of beneficial effects among patients treated with 
ART. However, a study among ART-naïve pregnant women did not show similar results. In contrast, 
supplementation of zinc was associated with an increased risk of wasting and anemia. Until these 
concerns are addressed by further research, caution is warranted for the use of zinc among people 
living with HIV.  
No apparent adverse effects on HIV progression have been detected with low-dose iron 
supplementation. However, the studies conducted do not exclude more subtle adverse effects of iron 
supplementation on HIV progression. Therefore only an RCT with a sufficient sample size to detect 
more subtle changes would be able to rule out potential adverse effects of iron.  
Small studies have indicated beneficial effects of selenium, NAC, or whey protein on HIV 
progression. However, these findings need to be confirmed by larger, well designed RCTs. 
Furthermore, probiotics and prebiotics have limited preliminary data for their use among people living 
with HIV and further research is warranted.  
An integrated approach that combines micronutrients with the various functional food components 
may have the greatest potential to delay HIV progression. A large multicenter trial, recently conducted 
in Europe, provides a prime example for this approach. The RCT among ART naïve patients (n = 370) 
showed that a novel formulation (not fully disclosed, but including prebiotic oligosaccharides with 
NAC, bovine colostrum, omega-3 poly-unsaturated fatty acids and a combination of vitamins and 
minerals) slowed down the decline of the CD4 count with 28 cells/μL in the intervention group, 
compared to −68 cells/μL among the placebo group after one year of supplementation (p < 0.05) [106]. 
This is very encouraging, although the formulation would be expensive and perhaps not so readily 
available to people living in developing countries.  
It should be emphasized that an adequate micronutrient intake among people living with HIV is best 
achieved through an adequate diet [7]. On the other hand, various interventions have been shown to 
have beneficial effects in dosages not feasible to be obtained from a diet or not naturally present in 
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high concentrations in food. Therefore, in addition to a diet-based approach, the development of 
functional food interventions specifically for people living with HIV are much needed. 
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